Cargando…

mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma

Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to investigate the relative efficacy of allosteric versus catalyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bailey, Sean T., Zhou, Bing, Damrauer, Jeffrey S., Krishnan, Bhavani, Wilson, Harper L., Smith, Aleisha M., Li, Mingqing, Yeh, Jen Jen, Kim, William Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152178/ https://www.ncbi.nlm.nih.gov/pubmed/25180793 http://dx.doi.org/10.1371/journal.pone.0104413

Ejemplares similares

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment
por: Cao, Jingwen, et al.
Publicado: (2016)

Expression of concern: Compensatory increase of transglutaminase 2 is responsible for resistance to mTOR inhibitor treatment
Publicado: (2020)

Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors
por: Xia, Yiqun, et al.
Publicado: (2021)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
por: Ho, Alan L., et al.
Publicado: (2012)

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
por: ANDERSEN, NICHOLAS J., et al.
Publicado: (2015)

Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma
por: Chadwick, Michelle L., et al.
Publicado: (2018)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2019)

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
por: Jefferies, Reece, et al.
Publicado: (2022)

MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma
por: Bailey, Sean T., et al.
Publicado: (2017)

Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
por: Viana, Sofia D., et al.
Publicado: (2018)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
por: Milella, Michele, et al.
Publicado: (2017)

Tanshinone IIA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway
por: Qian, Jun, et al.
Publicado: (2020)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

mTOR: An attractive therapeutic target for osteosarcoma?
por: Ding, Liu, et al.
Publicado: (2016)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
por: Tran, Khanh B., et al.
Publicado: (2021)

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
por: Ewald, Florian, et al.
Publicado: (2015)

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
por: Heavey, Susan, et al.
Publicado: (2016)

A conjugated mTOR/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery
por: Tao, Qiangqiang, et al.
Publicado: (2020)

Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway
por: Yeh, Tzu-Shao, et al.
Publicado: (2014)

Optimising the use of mTOR inhibitors in renal transplantation
por: Russ, Graeme R
Publicado: (2013)

Astragalus membranaceus Enhances Myotube Hypertrophy through PI3K-Mediated Akt/mTOR Signaling Phosphorylation
por: Yeh, Tzu-Shao, et al.
Publicado: (2022)

mTOR: A Potential Therapeutic Target in Osteoarthritis?
por: Pal, Bandna, et al.
Publicado: (2015)

Targeting mTOR as a Therapeutic Approach in Medulloblastoma
por: Aldaregia, Juncal, et al.
Publicado: (2018)

mTOR Signaling and Potential Therapeutic Targeting in Meningioma
por: Pinker, Benjamin, et al.
Publicado: (2022)

mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target
por: Raychaudhuri, Smriti K, et al.
Publicado: (2014)

mTOR kinase is a therapeutic target for respiratory syncytial virus and coronaviruses
por: Huynh, HoangDinh, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways
por: Tiwary, R, et al.
Publicado: (2011)

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
por: Dembla, Vikas, et al.
Publicado: (2017)

The Role of mTOR Signaling as a Therapeutic Target in Cancer
por: Popova, Nadezhda V., et al.
Publicado: (2021)

Modulation of mTOR and epigenetic pathways as therapeutics in gallbladder cancer
por: Yang, Dong, et al.
Publicado: (2020)

mTOR pathway – a potential therapeutic target in stroke
por: Melanis, Konstantinos, et al.
Publicado: (2023)

Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives
por: Gargalionis, Antonios N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gc253j35gisp9pibngf6gejljv